From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma

A. Thomas, A. Rajan, A. Lopez-Chavez, Y. Wang, G. Giaccone

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Although tumor molecular-profile-directed therapy appears promising in early clinical studies, there are many practical challenges to its successful clinical application in non-small-cell lung cancer (NSCLC). These challenges may be broadly classified as those relating to tumor (heterogeneity), tissue (acquisition and processing), testing (assays for molecular profiling) and trials (clinical evaluation of molecular markers and drugs). Strategies to overcome these challenges include (i) understanding the biological basis of tumor heterogeneity and of carcinogenesis in the large subset of patients with no currently evident driver events; (ii) technological advances in minimally invasive acquisition of tumor and nextgeneration sequencing (NGS) which would enable single-platform analysis of molecular alterations in limited tissue at a reasonable turnaround time (TAT); (iii) deliberation in early stages of drug development as well as clinical trial design to identify, validate and assess the clinical utility of biomarkers in conjunction with drugs and (iv) collaboration to improve understanding of and accrual to trials enrolling patients with rare molecular alterations.

Original languageEnglish (US)
Article numbermds478
Pages (from-to)577-585
Number of pages9
JournalAnnals of Oncology
Volume24
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Molecular Targeted Therapy
Non-Small Cell Lung Carcinoma
Neoplasms
Clinical Trials
Pharmaceutical Preparations
Carcinogenesis
Biomarkers

Keywords

  • Molecular profiling
  • Next-generation sequencing
  • Non-small-cell lung cancer
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Thomas, A., Rajan, A., Lopez-Chavez, A., Wang, Y., & Giaccone, G. (2013). From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Annals of Oncology, 24(3), 577-585. [mds478]. https://doi.org/10.1093/annonc/mds478

From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. / Thomas, A.; Rajan, A.; Lopez-Chavez, A.; Wang, Y.; Giaccone, G.

In: Annals of Oncology, Vol. 24, No. 3, mds478, 03.2013, p. 577-585.

Research output: Contribution to journalArticle

Thomas, A, Rajan, A, Lopez-Chavez, A, Wang, Y & Giaccone, G 2013, 'From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma', Annals of Oncology, vol. 24, no. 3, mds478, pp. 577-585. https://doi.org/10.1093/annonc/mds478
Thomas, A. ; Rajan, A. ; Lopez-Chavez, A. ; Wang, Y. ; Giaccone, G. / From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. In: Annals of Oncology. 2013 ; Vol. 24, No. 3. pp. 577-585.
@article{84f611532375414db4c2f08486d9b487,
title = "From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma",
abstract = "Although tumor molecular-profile-directed therapy appears promising in early clinical studies, there are many practical challenges to its successful clinical application in non-small-cell lung cancer (NSCLC). These challenges may be broadly classified as those relating to tumor (heterogeneity), tissue (acquisition and processing), testing (assays for molecular profiling) and trials (clinical evaluation of molecular markers and drugs). Strategies to overcome these challenges include (i) understanding the biological basis of tumor heterogeneity and of carcinogenesis in the large subset of patients with no currently evident driver events; (ii) technological advances in minimally invasive acquisition of tumor and nextgeneration sequencing (NGS) which would enable single-platform analysis of molecular alterations in limited tissue at a reasonable turnaround time (TAT); (iii) deliberation in early stages of drug development as well as clinical trial design to identify, validate and assess the clinical utility of biomarkers in conjunction with drugs and (iv) collaboration to improve understanding of and accrual to trials enrolling patients with rare molecular alterations.",
keywords = "Molecular profiling, Next-generation sequencing, Non-small-cell lung cancer, Tumor heterogeneity",
author = "A. Thomas and A. Rajan and A. Lopez-Chavez and Y. Wang and G. Giaccone",
year = "2013",
month = "3",
doi = "10.1093/annonc/mds478",
language = "English (US)",
volume = "24",
pages = "577--585",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma

AU - Thomas, A.

AU - Rajan, A.

AU - Lopez-Chavez, A.

AU - Wang, Y.

AU - Giaccone, G.

PY - 2013/3

Y1 - 2013/3

N2 - Although tumor molecular-profile-directed therapy appears promising in early clinical studies, there are many practical challenges to its successful clinical application in non-small-cell lung cancer (NSCLC). These challenges may be broadly classified as those relating to tumor (heterogeneity), tissue (acquisition and processing), testing (assays for molecular profiling) and trials (clinical evaluation of molecular markers and drugs). Strategies to overcome these challenges include (i) understanding the biological basis of tumor heterogeneity and of carcinogenesis in the large subset of patients with no currently evident driver events; (ii) technological advances in minimally invasive acquisition of tumor and nextgeneration sequencing (NGS) which would enable single-platform analysis of molecular alterations in limited tissue at a reasonable turnaround time (TAT); (iii) deliberation in early stages of drug development as well as clinical trial design to identify, validate and assess the clinical utility of biomarkers in conjunction with drugs and (iv) collaboration to improve understanding of and accrual to trials enrolling patients with rare molecular alterations.

AB - Although tumor molecular-profile-directed therapy appears promising in early clinical studies, there are many practical challenges to its successful clinical application in non-small-cell lung cancer (NSCLC). These challenges may be broadly classified as those relating to tumor (heterogeneity), tissue (acquisition and processing), testing (assays for molecular profiling) and trials (clinical evaluation of molecular markers and drugs). Strategies to overcome these challenges include (i) understanding the biological basis of tumor heterogeneity and of carcinogenesis in the large subset of patients with no currently evident driver events; (ii) technological advances in minimally invasive acquisition of tumor and nextgeneration sequencing (NGS) which would enable single-platform analysis of molecular alterations in limited tissue at a reasonable turnaround time (TAT); (iii) deliberation in early stages of drug development as well as clinical trial design to identify, validate and assess the clinical utility of biomarkers in conjunction with drugs and (iv) collaboration to improve understanding of and accrual to trials enrolling patients with rare molecular alterations.

KW - Molecular profiling

KW - Next-generation sequencing

KW - Non-small-cell lung cancer

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=84874575400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874575400&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds478

DO - 10.1093/annonc/mds478

M3 - Article

VL - 24

SP - 577

EP - 585

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

M1 - mds478

ER -